Answers are grounded in this paper and cite their sources.
Investigates PCK1's role in renal fibrosis after AKI, suggesting a potential therapy.
The transition from acute kidney injury (AKI) to chronic kidney disease (CKD) is characterized by progressive renal fibrosis, yet the key tubular regulatory factors driving this maladaptive repair remain inadequately defined. In this study, we investigated the role of phosphoenolpyruvate carboxykinase 1 (PCK1), the rate-limiting enzyme of gluconeogenesis, in the AKI-to-CKD transition. Analysis of human single-cell RNA sequencing (scRNA-seq) datasets revealed a profound downregulation of PCK1 in injured proximal tubule cells, which correlated with the upregulation of pro-fibrotic markers. In rodent models, we demonstrated that the loss of PCK1 precedes significant collagen deposition and acts as a primary driver of fibrogenesis. Mechanistically, PCK1 deficiency enhanced TGF-β1-induced Smad3 phosphorylation and nuclear translocation, whereas PCK1 overexpression suppressed Smad3 activation as well as the expression of fibrosis-related genes and proteins. Our functional assays supported that PCK1 serves as an endogenous negative regulator and antagonist of Smad3, its depletion releases the restraint on Smad3 phosphorylation and nuclear translocation, leading to the loss of tubular epithelial identity. Significantly, the pharmacological or genetic restoration of PCK1 effectively blunted Smad3 activation and attenuated renal fibrosis in vitro. These findings identify PCK1 as a critical metabolic regulator that maintains tubular homeostasis and suggest that PCK1-targeted modulation of Smad3 signaling may be a promising therapeutic strategy for arresting the progression of chronic kidney disease following acute injury. PCK1 inhibits tubular Smad3 signaling and fibrotic progression during AKI-to-CKD transition. Acute injuries suppress the expression of tubular gluconeogenic enzyme PCK1 (green circle) and promote progressive renal fibrosis. In healthy tubules, PCK1 sustains gluconeogenesis and restrains Smad3 activation (red), whereas injury-associated PCK1 loss permits TGF-β-driven Smad3 phosphorylation and nuclear translocation. The pro-fibrotic programs are marked by increased fibronectin, collagens, α-SMA, as well as extracellular matrix accumulation and myofibroblast activation
No takes yet. Share an insight, caveat, or question.
Gan et al. (2026) studied this question.
Synapse has enriched 10 related papers. Consider them for comparative context: